Erwied Patrick, Gu Yi, Simon Lena, Schneider Martin, Helm Dominic, Michel Maurice Stefan, Nuhn Philipp, Nitschke Katja, Worst Thomas Stefan
Department of Urology and Urosurgery, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.
Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Discov Oncol. 2024 Aug 27;15(1):374. doi: 10.1007/s12672-024-01248-x.
To improve the prognosis of bladder and prostate cancer, highly specific and sensitive biomarkers are needed for early detection, prognosis prediction, and therapeutic stratification. Extracellular vesicles (EV) from plasma could fill this gap due to their potential to serve as cancer biomarkers. However, the enrichment of EV is a major challenge, because the highly abundant plasma proteins are interfering with analytical downstream applications like mass spectrometry (MS). Therefore, the purity requirements of the EV samples must be carefully considered when selecting or developing a suitable EV enrichment method. The aim of this study was to compare a self-designed EV enrichment method based on density cushion centrifugation (DCC) combined with size exclusion chromatography (SEC) and concentration (method 1) with the exoRNeasy midi kit from Qiagen (method 2) and with unprocessed plasma. Furthermore, the single steps of method 1 were evaluated for their effectiveness to enrich EV from plasma. The results showed that the EV samples enriched with method 1 contained the highest levels of EV and exosome markers with simultaneously low levels of highly abundant plasma proteins. In summary, the combination of DCC, SEC and concentration proved to be a promising approach to discover EV-based biomarkers from plasma of cancer patients.
为改善膀胱癌和前列腺癌的预后,需要高特异性和高灵敏度的生物标志物用于早期检测、预后预测和治疗分层。血浆来源的细胞外囊泡(EV)因其有潜力作为癌症生物标志物,有望填补这一空白。然而,EV的富集是一项重大挑战,因为血浆中高丰度的蛋白质会干扰诸如质谱分析(MS)等下游分析应用。因此,在选择或开发合适的EV富集方法时,必须仔细考虑EV样品的纯度要求。本研究的目的是将基于密度梯度离心(DCC)结合尺寸排阻色谱(SEC)和浓缩的自行设计的EV富集方法(方法1)与Qiagen公司的外泌体RNA提取试剂盒(方法2)以及未处理的血浆进行比较。此外,还评估了方法1的各个步骤从血浆中富集EV的有效性。结果表明,用方法1富集的EV样品中EV和外泌体标志物水平最高,同时高丰度血浆蛋白水平较低。总之,DCC、SEC和浓缩相结合被证明是一种从癌症患者血浆中发现基于EV的生物标志物的有前景的方法。